mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Trial Details

NCT ID

NCT06249321

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• mFOLFIRINOX plus IMRT

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Ability to understand and the willingness to sign a written informed consent document.
• Age ≥ 18 years and ≤ 80 years.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Histologically or cytologically confirmed advanced pancreas adenocarcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.